Loss of Indoleamine-2,3-Dioxygenase-1 (IDO1) in Knockout Mice Does Not Affect the Development of Skin Lesions in the Imiquimod-Induced Mouse Model of Psoriasis.
Imiquimod (IMQ)
T cells
indoleamine-2,3-dioxygenase (IDO)
inflammation
kynureninase
kynurenine
psoriasis
skin
tryptophan
Journal
International journal of tryptophan research : IJTR
ISSN: 1178-6469
Titre abrégé: Int J Tryptophan Res
Pays: United States
ID NLM: 101513378
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
07
2021
accepted:
17
01
2022
entrez:
7
3
2022
pubmed:
8
3
2022
medline:
8
3
2022
Statut:
epublish
Résumé
Indoleamine-2,3-dioxygenase (IDO) degrades the essential amino acid tryptophan resulting in tryptophan depletion and the accumulation of catabolites such as kynurenine. The expression/activity of IDO in various cells, including macrophages and dendritic cells, results in an inhibition of T-cell responses in a number of situations, such as toward allogeneic fetuses and tissue grafts. Psoriasis is an immune-mediated skin disease involving T cells; kynureninase and its generation of catabolites downstream of IDO are reported to play an important role in this disease. We hypothesized that mice lacking the IDO1 gene would exhibit a hyperactive immune response and an exacerbation of skin lesions in the imiquimod-induced mouse model of psoriasis. Littermate wild-type and IDO1-knockout mice were treated with imiquimod for 5 days, and the severity of psoriasiform skin lesions assessed using the psoriasis area and severity index (PASI), ear edema measured using a digital caliper, and thickness of the epidermis determined by histology. Expression of pro-inflammatory mediators and tryptophan-metabolizing enzymes was monitored using quantitative RT-PCR. Imiquimod increased ear edema, PASI scores, and epidermal thickness in both WT and IDO1 knockout mice; however, there were no differences observed between the 2 genotypes. There were also no differences in imiquimod's induction of skin inflammatory mediators, indicating no effect of IDO1 gene loss in this psoriasis model. Although these data suggest a lack of involvement of IDO1 in psoriatic skin inflammation, other possible mechanisms, such as compensatory changes in other pathways and the involvement of the IDO2 isoform, must also be considered.
Identifiants
pubmed: 35250276
doi: 10.1177/11786469221078191
pii: 10.1177_11786469221078191
pmc: PMC8891896
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11786469221078191Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Trends Immunol. 2013 Mar;34(3):137-43
pubmed: 23103127
Int J Mol Sci. 2020 Aug 01;21(15):
pubmed: 32752186
J Invest Dermatol. 2019 Apr;139(4):868-877
pubmed: 30391260
Eur J Immunol. 2013 Dec;43(12):3138-46
pubmed: 24254490
PLoS One. 2011 Apr 04;6(4):e18266
pubmed: 21483750
Vaccines (Basel). 2015 Sep 10;3(3):703-29
pubmed: 26378585
PLoS One. 2014 Mar 07;9(3):e91146
pubmed: 24608112
J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401-7
pubmed: 10459113
Dermatol Ther. 2020 Jul;33(4):e13800
pubmed: 32530083
Science. 1998 Aug 21;281(5380):1191-3
pubmed: 9712583
J Allergy Clin Immunol. 2016 Jun;137(6):1830-1840
pubmed: 26725996
Trends Immunol. 2016 Mar;37(3):193-207
pubmed: 26839260
Front Immunol. 2020 Sep 29;11:1984
pubmed: 33133059
Int J Mol Sci. 2021 Oct 26;22(21):
pubmed: 34769005
J Dermatol Sci. 2004 Dec;36(3):157-64
pubmed: 15541637
Cell Transplant. 2018 Mar;27(3):557-570
pubmed: 29759005
Front Immunol. 2017 Oct 27;8:1360
pubmed: 29163470
Int J Exp Pathol. 2009 Jun;90(3):232-48
pubmed: 19563608
JAMA Dermatol. 2013 Oct;149(10):1173-9
pubmed: 23925466
J Am Acad Dermatol. 2017 Mar;76(3):393-403
pubmed: 28212760
J Dermatolog Treat. 2008;19(1):5-21
pubmed: 18273720
J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
pubmed: 15083780
J Immunol. 2009 May 1;182(9):5836-45
pubmed: 19380832